A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms MAPS2
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2017 According to a Bristol-Myers Squibb media release, data from the study will be presented at the 2017 American Society of Clinical Oncology (ASCO).
- 05 Jun 2017 Results published in a Bristol-Myers Squibb media release.